{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:05:09Z","timestamp":1780553109314,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mirogabalin, a novel third-generation \u03b12-\u03b4 calcium channel ligand, is approved for diabetic peripheral neuropathic pain (DPNP). However, its post-marketing safety profile remains insufficiently characterized, particularly regarding novel signals and comparative safety profiles with established therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to identify and characterize adverse event (AE) signals associated with mirogabalin, evaluate demographic differences, and compare signal strength with pregabalin and gabapentin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database (January 2019\u2013June 2025). Disproportionality analysis was performed using the Reporting Odds Ratio (ROR) and Information Component (IC) methods. Subgroup analyses by sex and age, sensitivity analyses restricted to monotherapy reports, and time-to-onset (TTO) analysis using Weibull modeling were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 463 healthcare professional-reported AE reports, 33 positive signals were identified. Beyond known AEs (e.g., dizziness, somnolence), six novel potential signals were detected: pleural effusion (n = 6), contusion (n = 4), toxic encephalopathy (n = 4), Cardiac failure congestive (n = 4), deafness (n = 3), and angioedema (n = 3). Head-to-head comparisons revealed that mirogabalin exhibited significantly higher reporting odds ratios (RORs) than pregabalin for pleural effusion (ROR = 2.39, 95%CI: 1.01\u20135.65), toxic encephalopathy (ROR = 6.37, 95%CI: 1.99\u201320.36), contusion (ROR = 3.35, 95%CI: 1.14\u20139.87), and deafness (ROR = 3.67, 95%CI: 1.04\u201312.91), and significantly higher RORs than gabapentin for cardiac failure congestive (ROR = 6.05, 95%CI: 1.78\u201320.54). Subgroup analysis revealed sex- and age-related differences: male patients showed higher reporting proportions of muscle weakness, myoclonus, erythema multiforme, urinary retention, and elevated liver enzymes, whereas females exhibited higher proportions of renal impairment and falls; elderly patients (\u226565\u00a0years) showed higher reporting frequencies of dizziness and rhabdomyolysis, whereas the 18\u201365 age group showed higher proportions of hepatic and cardiovascular events. Sensitivity analysis partially supported the stability of some signals, with rhabdomyolysis identified exclusively in monotherapy reports. The median TTO was 6\u00a0days (IQR: 2\u201342), indicating an early-clustering pattern (\u03b2 = 0.55, 95% CI: 0.50\u20130.60). Sensitivity analysis after excluding outliers yielded a median TTO of 5 days (IQR: 2\u201328) with \u03b2 = 0.72 (95% CI: 0.65\u20130.80).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study extends the understanding of mirogabalin\u2019s post-marketing safety profile by identifying six novel signals and revealing distinct safety signal profiles compared with established \u03b12-\u03b4 ligands. Demographic-stratified monitoring strategies are warranted to optimize patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1833433","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:43:27Z","timestamp":1780551807000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-marketing safety evaluation of mirogabalin using the JADER database"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinjuan","family":"Sun","sequence":"first","affiliation":[{"name":"Nanjing University of Chinese Medicine Affiliated Junxie Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyi","family":"Li","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Affiliated Junxie Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gai","family":"Li","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Affiliated Junxie Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Affiliated Junxie Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Affiliated Junxie Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Lu","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Affiliated Junxie Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Affiliated Junxie Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin\u2019an","family":"Chen","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Affiliated Junxie Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Wang","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Affiliated Junxie Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40200-020-00661-7","article-title":"Prevalence and associated factors of painful diabetic peripheral neuropathy among diabetic patients on follow up at jimma university medical center","volume":"19","author":"Abdissa","year":"2020","journal-title":"J. Diabetes Metab. Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1248\/bpb.b19-00156","article-title":"Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS","volume":"42","author":"Ando","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jdi.13013","article-title":"Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients","volume":"10","author":"Baba","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"B5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.clinph.2014.07.016","article-title":"Gabapentin-induced encephalopathy","volume":"126","author":"Beauvais","year":"2015","journal-title":"Clin. Neurophysiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.6705\/j.jacme.202106_11(2).0005","article-title":"Gabapentin-induced angioedema of tongue","volume":"11","author":"Chong","year":"2021","journal-title":"J. Acute Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ndt\/gfaf177","article-title":"IDF diabetes atlas 11th edition 2025: global prevalence and projections for 2050","volume":"41","author":"Duncan","year":"2025","journal-title":"Nephrol. Dial. Transpl"},{"key":"B3","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/S0140-6736(21)00516-X","article-title":"Hearing loss prevalence and years lived with disability, 1990-2019: findings from the global burden of disease study 2019","volume":"397","author":"GBD 2019 Hearing Loss Collaborators","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000026537","article-title":"Renal impairment as a possible side effect of Gabapentin. A single case report","volume":"38","author":"Grunze","year":"1998","journal-title":"Neuropsychobiology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40122-024-00617-2","article-title":"A phase 3, multicenter, randomized, double-blind, placebo-controlled 14-Week study of mirogabalin in Chinese patients with diabetic peripheral neuropathic pain","volume":"13","author":"Guo","year":"2024","journal-title":"Pain Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.clinthera.2021.03.015","article-title":"Safety and efficacy of mirogabalin for peripheral neuropathic pain: pooled analysis of two pivotal phase III \u015btudies","volume":"43","author":"Kato","year":"2021","journal-title":"Clin. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"112807","DOI":"10.1016\/j.biopha.2022.112807","article-title":"Gabapentinoid-induced peripheral edema and acute heart failure: a translational study combining pharmacovigilance data and in vitro animal experiments","volume":"149","author":"Largeau","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.yebeh.2012.08.002","article-title":"Pregabalin intoxication-induced encephalopathy with triphasic waves","volume":"25","author":"Lee","year":"2012","journal-title":"Epilepsy Behav."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1212\/01.wnl.0000145767.36287.a1","article-title":"Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial","volume":"63","author":"Lesser","year":"2004","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"110602","DOI":"10.1016\/j.diabres.2023.110602","article-title":"Prevalence of painful diabetic peripheral neuropathy in type 2 diabetes mellitus and diabetic peripheral neuropathy: a nationwide cross-sectional study in mainland China","volume":"198","author":"Li","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6491","DOI":"10.2147\/JPR.S547736","article-title":"Gabapentinoids-induced rhabdomyolysis\/myopathy: Clinical characteristics, management, outcomes, and critical safety alerts","volume":"18","author":"Liu","year":"2025","journal-title":"J. Pain Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.aller.2011.09.012","article-title":"Challenge-based pregabalin induced urticaria and angioedema. A case report","volume":"40","author":"Ortega-Camarero","year":"2012","journal-title":"Allergol. Immunopathol. Madr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12933-022-01610-9","article-title":"Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy","volume":"21","author":"Pan","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2524451","DOI":"10.1001\/jamanetworkopen.2025.24451","article-title":"Initiation of pregabalin vs gabapentin and development of heart failure","volume":"8","author":"Park","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.clinthera.2008.09.004","article-title":"A probable case of gabapentin-related reversible hearing loss in a patient with acute renal failure","volume":"30","author":"Pierce","year":"2008","journal-title":"Clin. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/ph17070838","article-title":"Sex-gender differences are completely neglected in treatments for neuropathic pain","volume":"17","author":"Salis","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0278-5846(03)00166-0","article-title":"Asterixis and toxic encephalopathy induced by Gabapentin","volume":"28","author":"Sechi","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4009\/jsdt.50.301","article-title":"Pregabalin-induced acute interstitial nephritis in a patient with normal renal function who required dialysis","volume":"50","author":"Takahashi","year":"2017","journal-title":"Jpn. J. Nephrol. Dial."},{"key":"B23","doi-asserted-by":"publisher","first-page":"112099","DOI":"10.1016\/j.diabres.2025.112099","article-title":"Prevalence and risk factors of painful diabetic neuropathy: a systematic review and meta-analysis","volume":"222","author":"Tao","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/j.clinthera.2021.03.015","article-title":"Safety and efficacy of mirogabalin for peripheral neuropathic pain: pooled analysis of two pivotal phase III studies","volume":"43","author":"Tatsumi","year":"2021","journal-title":"Clin. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3265\/Nefrologia.pre2011.Nov.11087","article-title":"Acute renal failure due to gabapentin. A case report and literature","volume":"32","author":"Torregrosa-de Juan","year":"2012","journal-title":"Nefrologia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40122-023-00513-1","article-title":"Long-Term safety and efficacy of mirogabalin for central neuropathic pain: a multinational, phase 3, 52-Week, open-label study in Asia","volume":"12","author":"Ushida","year":"2023","journal-title":"Pain Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"CD007938","DOI":"10.1002\/14651858.CD007938.pub4","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s40122-025-00771-1","article-title":"Calcium channel \u03b12\u03b4 ligands mirogabalin, pregabalin, and gabapentin: advancements in diabetic peripheral neuropathic pain therapeutics","volume":"14","author":"Wu","year":"2025","journal-title":"Pain Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.26689\/par.v9i3.10767","article-title":"A real-world study on adverse events related to mirogabalin based on the VigiAccess database","volume":"9","author":"Xi","year":"2025","journal-title":"Proc. Anticancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5505\/agri.2018.48753","article-title":"A probable case of pregabalin - related reversible hearing loss","volume":"32","author":"Y\u0131lmaz","year":"2020","journal-title":"Agri"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3000605241257776","DOI":"10.1177\/03000605241257776","article-title":"Pregabalin-induced rhabdomyolysis: a case series and literature analysis","volume":"52","author":"Zhai","year":"2024","journal-title":"J. Int. Med. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1833433\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:43:29Z","timestamp":1780551809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1833433\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":31,"alternative-id":["10.3389\/fphar.2026.1833433"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1833433","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1833433"}}